ANZCTR search results

To compare changes in blood sugar levels (glycemic index) after consumption of bread made with the new wheat flour with the response obtained following consumption of bread manufactured from conventional wheat flour.

All hospitals in NSW are working towards becoming “Smoke Free Environments”. Patients are no longer be able to smoke in hospital. The study aims to analyse: - The effectiveness of opportunistic intervention in smokers about to undergo surgery; Perioperative effects (physiological and physical) of short notice cessation of smoking up to six weeks prior to surgery.

This study tests whether Temgesic improves the effectiveness of exposure therapy for decreasing social anxiety symptoms. We predict that individuals from the community diagnosed with social phobia who receive four exposure therapy sessions in combination with Temgesic will experience a greater reduction in social anxiety symptoms in comparison to individuals who received the placebo in combination with four exposure therapy sessions. Participants receive, in total, five weekly group therapy sessions, the first is educational and the next four consist of public speaking exposure therapy. One month post intervention participants are assessed for social anxiety symptoms as well as other general health indicators. All subjects, therapists, assessors, and data entry staff are blind to condition.

This study tests whether oxytocin facilitates the processing of human faces by enhancing memory and attractiveness towards exposed faces. Participants are assigned to Oxytocin or Placebo and then given a presentation of facial expressions. Participants must rate the attractiveness of each face. The next day, participants return to be assessed for their memory of faces and their attractiveness toward each face. THe hypothesis is that participants who were exposed to facial expressions with oxytocin will demonstrate better memory and greater attractiveness rating for these faces the next day than participants assigned to placebo. All participants, assessors, and research staff handling data are blind to condition.

This study looks at the effects of the drug capecitabine with or without bevacizumab in the treatment of patients with stage III colorectal cancer. You can join this study if you have cancer of the back passage (rectum) or large bowel (colon). Trial details: Participants will be divided into two groups. One group will receive oral capecitabine (from day 1 to day 14, rest for 7 days then repeat every 3 weekly for a total of 8 cycles), plus intravenous(IV) bevacizumab (one dose on day 1, repeated every 3 weekly for 16 cycles). The other group will receive capecitabine alone (from day 1 to day 14, rest for 7 days then repeat every 3 weekly for a total of 8 cycles), which is standard treatment. New preventative chemotherapies have been developed to reduce the risk of relapse of colorectal cancer. QUASAR2 uses a new combination of an oral chemotherapy drug (capecitabine) and a molecularly targeted therapy (bevacizumab), to determine whether this is more effective and less toxic than capecitabine alone. Colorectal cancer is the most commonly occurring cancer in Australia (excluding non-melanomic skin cancer), and the second most common cancer-related cause of death, responsible for 4,447 deaths in 2003 (1) As many as 40% of patients who undergo potentially curative treatment will ultimately relapse and die of metastatic disease. This observation has led to the development of adjuvant chemotherapies which reduce the risk of relapse. QUASAR2 uses a new combination for adjuvant therapy: an oral chemotherapy drug (capecitabine) and a molecularly targeted therapy (bevacizumab), to define whether this is superior in efficacy and less in toxicity than capecitabine alone, which is a standard of care in this disease.

To test whether six months' oral treatment with unregistered drug MKTVIF75HV improves magnetic resonance imaging brain scans in people with relapsing remitting multiple sclerosis.

Aims: Certain patients have a narrowing in the blood vessel that supplies blood to the brain. If this blood vessel gets blocked these patients can suffer a stroke because there is no blood flow to that part of the brain. One method of keeping this blood vessel open is a procedure where a special line is inserted into the blood vessel and a balloon is inflated. Inflating the balloon will cause the blood vessel to get bigger. To make sure that the blood vessel stays open a device called a stent (like a rigid internal pipe) is placed as well. This procedure is called carotid angioplasty and stenting. However, making the blood vessel bigger in this way can activate a nerve which can act on the heart, which can cause the heart rate and blood pressure to change significantly. Glycopyrrolate is a drug which is commonly used to increase a patient’s heart rate. In this study, glycopyrrolate, is given before the balloon is inflated to try to prevent the changes in heart rate and blood pressure. The aims of the study are to see if giving glycopyrrolate can prevent the changes in heart rate and blood pressure as well as improving the outcome of the patient after the procedure. Methodology: Information will be collected on the patient’s medical problems before the procedure. Patients will then be randomised to receive either an injection of glycopyrrolate or water before balloon inflation. Complications during the procedure will be noted such as changes in heart rate, blood pressure and electrocardiograph changes. If the patient does develop changes in heart rate or blood pressure, rescue medications will be available. After the procedure, cardiovascular and neurological complications will be noted. Blinding: Double blind: Non-participating anaesthetist will open a sealed opaque envelope and draw up either glycopyrrolate or water (to an equal volume) and give it to the participating anaesthetist to administer. Neither the patient or the participating anaesthetist will know if the drug is glycopyrrolate or placebo.

Iron deficiency anaemia is a common problem in pregnancy. It is often treated with high dose iron that cause constipation, stomach cramp and inhibit zinc absorption. Despite these concerns, there are no studies designed to work out the best dose of iron to treat anaemia in pregnancy. The aim of the study is to determine the dose that is most effective for the treatment of anaemia with least side effects. Three doses of iron (20mg/d, 40mg/d and 80mg/d) will be tested, and haemoglobin response and gastrointestinal side-effects will be assessed as the primary outcome. All researchers involved in the data collection and data analysis were blinded to the group allocation of the subjects until the primary analysis was completed.

This project aims to determine the best preventive methods for ECC by assessing variations of strategies. The strategies that will be used are • Education classes to antenatal and new parent groups • Preventive agents – participants will be randomly assigned to the following groups: toothbrushing with low-dose fluoride toothpaste, toothbrushing with 0.2 percent chlorhexidine gel, and toothbrushing with casein-phosphoprotein gel (CPP-ACP, Tooth Mousse) • Support through home visits and phone calls The effectiveness of these strategies will be assessed through • Pre and post questionnaires including dental knowledge, feeding practices and oral hygiene practices • Microbial analysis for the presence of decay-causing bacteria (blinded) • Dental screen analysis of participants having home visits (calibrated operators, not blinded) • Dental screen analysis at the 2 year recall (blinded) • Statistical analysis of data for case and control groups Participants will be recruited either from antenatal classes, pre-registration for maternity ward or new parent classes. All participants will be recalled when their child is approximately 6-9 months, 9-12 months and 15-18 months either through the home visit or by telephone. All will be asked to attend an appointment at the 24-26 month recall with their child. Swab samples of the teeth and gums will be taken and tested for the presence of decay-causing bacteria (mutans streptococci) and general oral bacteria in which participants will be informed of the results. The Mother’s teeth will be wiped with sterile cotton-tipped swabs at the initial contact, when the child is born and at the final recall. Those who wish to participate in home visits will also have their teeth swabbed at the 6-9 month period and their child’s teeth will be swabbed when their child is 6-9 months, 9-12 months and 15-18 months. Resources such as toothbrushes and preventive products will be supplied free of charge for the duration of participation or until the child is 24-26 months.

To discover if the consumption of foods made from CSIRO barley leads to changes in the levels of substances in the plasma (such as cholesterol) that would suggest they are beneficial for heart health.